OP
CRSP icon

ORG Partners’s CRISPR Therapeutics CRSP Stock Holding History

ORG Partners’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$1.73K Hold
33
– – ﹤0.01% 1463
2025
Q3 		$2.14K Buy
+33
New +$1.9K ﹤0.01% 1302
2025
Q1 		– Sell
-15
Closed -$590 – 1441
2024
Q4 		$590 Hold
15
– – ﹤0.01% 1176
2024
Q3 		$704 Hold
15
– – ﹤0.01% 1028
2024
Q2 		$809 Buy
+15
New +$868 ﹤0.01% 1583
2023
Q4 		– Sell
-15
Closed -$680 – 1173
2023
Q3 		$680 Buy
+15
New +$775 ﹤0.01% 1182

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
GP
GSK plc London $599M AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ORG Partners's CRSP Position: Q4 2025 in Review

ORG Partners held its CRISPR Therapeutics (CRSP) position steady in Q4 2025 at 33 shares worth $1.73K. The position accounts for ﹤0.01% of the portfolio, ranked #1463.

ORG Partners first reported a position in CRSP in Q3 2023 and has held it in 6 quarters since. The position peaked at $2.14K in Q3 2025. 479 funds tracked by Wall St. Rank hold CRSP as of Q4 2025.

  • ORG Partners held 33 shares of CRISPR Therapeutics worth $1.73K as of Q4 2025.
  • ORG Partners left its CRISPR Therapeutics share count unchanged in Q4 2025.
  • CRISPR Therapeutics made up ﹤0.01% of ORG Partners's portfolio in Q4 2025, its #1463 holding.
  • ORG Partners first reported a position in CRISPR Therapeutics in Q3 2023 and has held it in 6 quarters since.
  • ORG Partners's CRISPR Therapeutics position peaked at $2.14K in Q3 2025.
  • 479 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2025.

Based on ORG Partners's 13F filing for Q4 2025, filed 14 Jan 2026.